摘要
目的观察不同用法的瑞舒伐他汀降脂治疗急性冠脉综合征(ACS)疗效及安全性。方法选择158例ACS合并高脂血症患者。随机分为4组:A组(38例)予瑞舒伐他汀钙片10 mg,1次/d;B组(40例)予瑞舒伐他汀钙片10 mg,1次/d,阿昔莫司胶囊250 mg,3次/d;C组(40例)予瑞舒伐他汀钙片20 mg,1次/d;D组(40例)予瑞舒伐他汀钙片20 mg,1次/d,阿昔莫司胶囊250 mg,3次/d,4组患者疗程均为12周。观察治疗后血脂水平、血脂达标率、超敏C反应蛋白(hsCRP)、不良反应及心血管不良事件(MACE)的发生率。结果治疗后B、D组降脂疗效优于A、C组,有显著性差异;虽然D组血脂达标率及降低总胆固醇(TC)水平优于B组,但不良反应明显增加。结论瑞舒伐他汀联(10 mg,3次/d)合阿昔莫司(250 mg,3次/d)能有效地降低血脂水平,提高血脂达标率,降低hsCRP水平和MACE发生率,且不良反应较少,值得临床推广应用。
Objective To evaluate the efficacy and safety of different uses of rosuvastatin on the patients with acute coronary syndrome（ACS）.Methods 158 ACS patients with hyperlipidemia were divided randomly into group A（n=38,receiving rosuvastatin 10 mg/d）,B（n=40,rosuvastatin 10 mg/d and acipimox 750 mg/d）,C（n=40,rosuvastatin 10 mg/d）,D（n=40, rosuvastatin 10 mg/d,acipimox 750 mg/d）.The treatment lasted for 12 weeks.The level of blood lipid,achievement rates of blood lipid,hsCRP,MACE were observed after treatment.Results After treatment,effect of down-regulating blood lipid in group B and C was better than that in group A and C.The achievement rate of blood lipid and down-regulating the level of total cholesterol（TC） in group D were better than those in group B,but the adverse reactions rate was higher than group B.Conclusion 10 mg/d rosuvastatin with acipimox could effectively down-regulate the level of blood lipid and rates of MACE,with fewer adverse reactions.It′s worth popularizing and applying in clinical therapy.
出处
《实用临床医药杂志》
CAS
2011年第15期19-21,36,共4页
Journal of Clinical Medicine in Practice
